🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

More content coming out to support European Society of Cardiology #ESC2024 presentations for Day #3. Looking forward to #FINEARTSHF and discussions on emerging role of nonsteroidal #MRA for HFmrEF/HFpEF Stay tuned for more JACC Journals content to supplement discussion. Link is below.

🔥 fresh SoA review 🔥 JACC Journals To supplement discussion of #MRA European Society of Cardiology News European Society of Cardiology We comprehensively examine the current evidence regarding MRAs for HF and the future direction of nonsteroidal MRA research while exploring the causes of MRA underutilization.

HFSA announces late-breaking research for 2024 annual meeting Check out: HuMAIN, FINEARTS, STEP HFpEF And I’ll be presenting CARE-HK in HF ⁦Mikhail Kosiborod⁩ ⁦Steve Greene⁩ cardiovascularbusiness.com/topics/profess…

Out in The Lancet Diabetes & Endocrinology, findings from NIH NHLBI ACTIV4a study of #SGLT2i in hospitalized pts w/ COVID19. Paired World Health Organization (WHO) meta-analysis finds #SGLT2i safe in COVID with no overall effect on clinical outcomes. Pragmatic, platform-trial design sets a novel paradigm for trial innovation

🚨Now in Journal of Cardiac Failure, rationale & design of newest #HF registry #CARE_HK in HF ✳️First prospective registry specifically designed to examine care for #HF pts at high risk for hyperkalemia. 🌎Multinational ‼️Stay tuned. 1st results ➡️ HFSA #HFSA2024 onlinejcf.com/article/S1071-…

Sotagliflozin improved symptoms, physical limitations, and #QoL within 4 months after worsening #heartfailure, with consistent benefits across baseline demographic and clinical characteristics. bit.ly/3B3BYzs #JACC #Sotagliflozin @DLBhattMD Mikhail Kosiborod

Improving symptoms is a major pt-centric 🥅 in WHF. In JACC Journals from #SOLOISTWHF, we report KCCQ changes with SGLT1/2 inhibitor, sotagliflozin 🎯 Sotagliflozin improves outcomes across the KCCQ spectrum 🎯 KCCQ benefits consistent across major subgroups and EF Dr. Deepak L. Bhatt

Congratulations BiykemBozkurt

Ambarish will be presenting the results of our recently completed Phase 2a HuMAIN trial of HU6, a novel controlled metabolic accelerator, as part of Late Breaking Clinical Science sessions. HFSA Saint Luke's Mid America Heart Institute

We present primary results of CARE-HK at Rapid Fire Late Breakers session on Sunday, Sep 29th. Design paper now out in Journal of Cardiac Failure Steve Greene Mikhail Kosiborod Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalemia or High Risk of Hyperkalemia:

Please join us for the Mount Sinai Fuster Heart Hospital Top Ten Topics in Clinical Cardiology #CME course on Friday, November 1, 2024, in #NYC. We have a great lineup of faculty! Link to Register: mssm.cloud-cme.com/course/courseo… David L. Reich, MD Mount Sinai Health System Icahn School of Medicine at Mount Sinai Ph.Gabriel Steg Marc Bonaca MD MPH

CMCA is pleased to welcome Atlantic Health as a Charter Member. AHS is the first member in New Jersey dedicated to improving the lives of those with #cardiometabolic disease.

🚨The primary results of CARE-HK registry were just released for #HFSA2024! 📌 This registry aims to compare RAASi treatment patterns with guidelines in patients at high risk for hyperK+ Check out the rationale & design, out in Journal of Cardiac Failure 🔗bit.ly/3B9RGZS

HuMAIN Phase II study of HU6 in obesity HFpEF More visceral fat loss vs lean mass loss. Overall appears safe. Pivotal Phase III studies needed to understand impact on clinical endpoints. Proud to see our work presented HFSA today. Mikhail Kosiborod Saint Luke's Mid America Heart Institute

The CARE-HK in HF (NCT04864795) registry enrolled adults with chronic HF treated with ACEi, ARB, or ARNi, and also receiving or indicated for MRA, with an increased risk for HK (eGFR <45, current HK [sK+ >5.0], or history of HK in the previous 24 mo). Data collected

Weekly #semaglutide 2.4 mg is associated with consistent reductions in #heartfailure outcomes in people with obesity-related #HFpEF and inflammation bit.ly/3NvuKah #JACC #Obesity Subodh Verma Mikhail Kosiborod

HFpEF is a high inflammatory state—and GLP-1 RAs like semaglutide could be the game-changer. The STEP-HFpEF trials show real promise: weight loss and improved QoL. Will this become SoC for obese HFpEF? (link.springer.com/article/10.100…) #HREV Marco Metra Mikhail Kosiborod Josephine Harrington, MD

This is a special Cardiology Grand Rounds I am grateful to do with Mikhail Kosiborod at Saint Luke's Mid America Heart Institute tomorrow morning. It’s been quite the ride working together.

Fired up to attend the Saint Luke's Mid America Heart Institute Dr Robert D Conn Heart Conference today organized by Andrew J Sauer MD, Michael Nassif and David Skolnick MD. The great Mikhail Kosiborod gets us started this morning! (And I get to talk about #ThePeoplesVentricle of course!)

Bittersweet final Mikhail Kosiborod lecture and celebratory send offs this week at Saint Luke's Mid America Heart Institute His contributions to advancing the scientific understanding of cardiometabolic disease, diabetes, heart failure and his leadership in advancing therapies are truly unrivaled.